Siddhesh Gosavi, Pranali Joshi, Vidur Bhogate, Sairaj Gawade, Pooja Sangelkar, Shraddha Kanekar
Siddhesh Gosavi1, Pranali Joshi2*, Vidur Bhogate3, Sairaj Gawade3, Pooja Sangelkar3, Shraddha Kanekar3
1Yashwantrao Bhonsale College of Pharmacy, University of Mumbai, Maharashtra, India.
2Department of Pharmaceutics, Yashwantrao Bhonsale College of Pharmacy, University of Mumbai, Maharashtra, India.
3Yashwantrao Bhonsale College of Pharmacy, University of Mumbai, Maharashtra, India.
Volume - 11,
Issue - 1,
Year - 2021
Rheumatoid arthritis is an autoimmune inflammatory disease which has affected almost 0.5-1% of total population in the world. It is the disease which causes inflammation in the joints due the attack of various inflammatory agent resulting in formation of antibody against body’s own self antigen. Various inflammatory mediators are activated during this immune response. Rheumatoid factor, tumor necrosis factor, peptidylargininedeiminase, Jak-STAT kinase are some of the major causes of rheumatoid arthritis. The main purpose of this work is to comparatively study various anti-arthritic drugs for their therapeutic dose, potency and their side effects, so that it will help in correct choice of medication to treat it. It will also provide most of the data related to treatment in a collaborated form. Different classes of drugs have been compared such as NSAIDS, Biologic and Non-biologic DMARDS, including adjuvants drugs. Nowadays combination therapy is also used which is also compared in this review article. All data related to combinations have been compiled by studying various articles and information from the books. Article also involves comparison of newer drugs and suggestion for which combination can be tried for better treatment of RA, based on study of drugs for their chemistry and compatibility.
Cite this article:
Siddhesh Gosavi, Pranali Joshi, Vidur Bhogate, Sairaj Gawade, Pooja Sangelkar, Shraddha Kanekar. Comparative Study on Treatment of Rheumatoid Arthritis. Asian J. Pharm. Tech. 2021; 11(1):5-12. doi: 10.5958/2231-5713.2021.00002.7
Siddhesh Gosavi, Pranali Joshi, Vidur Bhogate, Sairaj Gawade, Pooja Sangelkar, Shraddha Kanekar. Comparative Study on Treatment of Rheumatoid Arthritis. Asian J. Pharm. Tech. 2021; 11(1):5-12. doi: 10.5958/2231-5713.2021.00002.7 Available on: https://ajptonline.com/AbstractView.aspx?PID=2021-11-1-2
1. Mohan Harsh, (2018), Textbook of Pathophysiology, Jaypee Brothers Medical Publishers, New Delhi.
2. Pike RM, Sulkin SE, Coggeshall HC, (1949); “Serological reactons in rheumatoid arthritis; factors affecting the agglutination of sensitized sheep erythrocytes in rheumatoid- arthritis serum”; J. Immunol; 63(4); 441-446.
3. Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T, (1987); “Rheumatoid factor secretion from human Leu-1+ B cells”; Science; 236(4797); 81-83.
4. Moynier M, Abderrazik M, Didry C, Sany J, Brochier J, (1992); “The B cell repertoire in rheumatoid arthritis. III. Preferential homing of rheumatoid factor-producing B cell precursor in the synovial fluid”; Arthritis Rheum; 35(1); 49-54.
5. Mageed RA, Borretzen M, Moyes SP, Thompson KM, Natvig JB, (1997); “Rheumatoid factor autoantibodies in health and disease”; Ann. NY Acad. Sci.; (815); 296-311.
6. Van Snick JL, Van Roost E, Markowetz B, Cambiaso CL, Masson PL, (1978); “Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes”; Eur. J. Immunol; 8(4); 279-285.
7. Brown PB, Nardella FA, MAnnik M, (1982); “Human complement activation by self- associated IgG rheumatoid factors”; Arthritis Rheum; 25(9); 1101-1107.
8. Grell M, Scheurich P, (2001); “Tumor Necrosis Factors. Encyclopedia of Life Sciences”; Nature Publishing Group, Chennai.
9. Choy EHS, Panayi GS, (2001); “Cytokine pathways and joint inflammation in rheumatoid arthritis”; NEJM; (344), 907–16.
10. Butler DM, Maini RN, Feldmann M, Brennan FM, (1995); “Modulation of proinflflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-α antibody with interleukin-1 receptor antagonist; Eur Cytokine Netw; (6), 225–30.
11. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M, (1991); “Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α”; Eur J Immunol; (21), 2575–9.
12. Halliwell B, (1995); “Oxygen radicals, nitric oxide and human inflammatory joint disease”; Ann Rheum Dis; (54), 505–10.
13. Deon D, Ahmed S, Tai K, et al., (2001); “Cross-Talk between IL-1 and IL-6 signaling pathways in Rheumatoid Arthritis synovial fibroblasts”; J Immunol; (167); 5395–403.
14. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, et al, (2007); “Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis”; Arthritis Rheum; (56); 1118–24.
15. McQueen FM, Benton N, Perry D, et al., (2003); “Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis”; Arthritis Rheum; (48); 1814–27.
16. Gravallese EM, Harada Y, Wang JT, et al., (1998); “Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis”; Am J Pathol; (152); 943–51.
17. Komine M, Kukita A, Kukita T, et al., (2001); “Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture”; Bone; (28); 474–83.
18. Kotake S, Udagawa N, Hakoda M, et al., (2001); “Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients”; Arthritis Rheum; (44); 1003–12.
19. Bartok B, Firestein GS., (2010); “Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis”; Immunol Rev; (233); 233–55.
20. Pettit AR, Ji H, von Stechow D, et al., (2001); “TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis”; Am J Pathol; (159); 1689–99.
21. Diarra D, Stolina M, Polzer K, et al., (2007); “Dickkopf-1 is a master regulator of joint remodeling”; Nat Med; (13); 156–63.
22. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW, (2002); “Signaling through the JAK/STAT pathway, recent advances and future challenges”; Gene; 285; 1-24.
23. Schindler CW, (2002); “JAK-STAT signaling in human disease”; J Clin Invest; (109); 1133-7.
24. Gadina M, Hilton D, Johnston JA, et al., (2001); “Signaling by type I and II cytokine receptors: ten years after”; Curr Opin Immunol; (13); 363-73.
25. Ivashkiv LB, Hu X, (2004); “Signaling by STATs”; Arthritis Res; (6); 159-68.
26. Chen W, Daines MO, Hershey GKK, (2004); “Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling”; J Allergy Clin Immunol; (114); 476-89.
27. Ernst M, Inglese M, Waring P, et al., (2001); “Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation”; J Exp Med; (194); 189-203.
28. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB; (1995); “Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids”; J Exp Med; (182); 1825-31.
29. Pamela Mangat, Natalia Wegner, Patrick J Venables and Jan Potempa, (2010); “Arthritis Research and Therapy”; (volume 12).
30. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmström V, Feldmann M, and Venables PJ, (2010); “Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis”; Immunol Rev; (233); 34-54. 10.
31. Tripathi KD, (2019), Essential of Medical Pharmacology, Jaypee Brothers Medical Publisher, New Delhi
32. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun 15; 59(6):762–784.
33. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, (2008); “American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis”; Arthritis Rheum; 59(6); 762-84.
34. Rajendra B. Pawade, Pramod P. Bhalerao, Rahul R. Kunkulol, Nilam S. Kute; “Disease-Modifying Anti-Rheumatic Drugs (DMARDs) used for Rheumatoid Arthritis- P”; 272-288.
35. Verstappen SM, Albada-Kuipers GA, Bijlsma JW, et al., (2005); “A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up”; Ann Rheum Dis; (64); 38-43.
36. Bruce N. Cronstein; (2005); “Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis”; The American Society for Pharmacology and Experimental Therapeutics; (57)
37. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun; 76(6):960–977.
38. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar; 73(3):492–509.
39. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL, (2011); “Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis”; J Rheumatol; 38(5); 855-62.
40. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, (2004); “Efficacy of Bcell-targeted therapy with rituximab in patients with rheumatoid arthritis”; N Engl J Med; 350(25); 2572-81.
41. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G., (2009); “Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study”; Ann Rheum Dis; 68(6); 805-11.
42. Singh JA, Saag, KG, Bridges SL Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):1–25.
43. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625–639.
44. Whittle S.L. and Hughes R.A.; (2004); “Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review”; Rheumatology; (43); 267–271.
45. Haire and Ana Fernandez James R O'Dell, Kara Petersen, Robert Leff, William Palmer, Eric Schned, Kent Blakely, Claire; (2006); “Treatment of rheumatoid arthritis. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold”; The Journal of Rheumatology; (33); 213-218.
46. Christos; (2006); “Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis”; The Journal of Rheumatology; (33); 486-489.